Caladrius Biosciences Stock Price, News & Analysis (NASDAQ:CLBS)

$3.50 0.43 (14.01 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$3.07
Today's Range$3.08 - $3.55
52-Week Range$2.63 - $7.79
Volume271,819 shs
Average Volume59,511 shs
Market Capitalization$33.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54

About Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences logoCaladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:CLBS
  • CUSIP: N/A
  • Web: www.caladrius.com
Debt:
  • Current Ratio: 5.78%
  • Quick Ratio: 4.84%
Sales & Book Value:
  • Annual Sales: $35.28 million
  • Price / Sales: 0.94
  • Book Value: $5.59 per share
  • Price / Book: 0.63
Profitability:
  • Trailing EPS: ($2.07)
  • Net Income: ($32,650,000.00)
  • Net Margins: -84.10%
  • Return on Equity: -96.80%
  • Return on Assets: -43.98%
Misc:
  • Employees: 209
  • Outstanding Shares: 9,470,000
 
Frequently Asked Questions for Caladrius Biosciences (NASDAQ:CLBS)

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative return on equity of 96.80% and a negative net margin of 84.10%. View Caladrius Biosciences' Earnings History.

Where is Caladrius Biosciences' stock going? Where will Caladrius Biosciences' stock price be in 2017?

1 analysts have issued 12-month price objectives for Caladrius Biosciences' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Caladrius Biosciences' share price to reach $7.00 in the next twelve months. View Analyst Ratings for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:

  • David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)
  • Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)
  • Douglas W. Losordo M.D., Chief Medical Officer (Age 58)
  • Gregory B. Brown M.D., Director (Age 64)
  • Richard J. Berman J.D., Independent Director (Age 73)
  • Drew Bernstein CPA., , Independent Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Steven Mark Klosk, Independent Director (Age 60)

How do I buy Caladrius Biosciences stock?

Shares of Caladrius Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of Caladrius Biosciences stock can currently be purchased for approximately $3.50.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $33.53 million and generates $35.28 million in revenue each year. The biotechnology company earns ($32,650,000.00) in net income (profit) each year or ($2.07) on an earnings per share basis. Caladrius Biosciences employs 209 workers across the globe.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 Allen Rd, BASKING RIDGE, NJ 07920-4500, United States. The biotechnology company can be reached via phone at +1-908-8420100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  284
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Caladrius Biosciences (NASDAQ:CLBS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (100.00% upside)
Consensus Price Target History for Caladrius Biosciences (NASDAQ:CLBS)
Price Target History for Caladrius Biosciences (NASDAQ:CLBS)
Analysts' Ratings History for Caladrius Biosciences (NASDAQ:CLBS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017HC WainwrightReiterated RatingBuy$7.00N/AView Rating Details
11/9/2016Chardan CapitalReiterated RatingBuy$6.50N/AView Rating Details
5/14/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyN/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)
Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Earnings History by Quarter for Caladrius Biosciences (NASDAQ CLBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.79)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.96)($0.88)ViewN/AView Earnings Details
5/18/2017Q1 2017($0.72)($1.12)$9.50 million$7.92 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.80)($0.73)$6.30 million$10.18 millionViewN/AView Earnings Details
11/7/2016Q3($1.55)($1.09)$7.70 million$9.32 millionViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.30)($0.21)$6.00 million$5.89 millionViewN/AView Earnings Details
8/6/2015Q215($0.32)($0.31)$5.20 million$5.87 millionViewN/AView Earnings Details
10/30/2014Q3 2014($0.41)($0.44)$4.00 million$4.12 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.28)($0.38)$4.70 million$4.49 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Caladrius Biosciences (NASDAQ:CLBS)
Current Year EPS Consensus Estimate: $-2.33 EPS
Next Year EPS Consensus Estimate: $-2.94 EPS

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Caladrius Biosciences (NASDAQ CLBS)
Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 6.36%
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Institutional Ownership by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ CLBS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Caladrius Biosciences (NASDAQ:CLBS)
Latest Headlines for Caladrius Biosciences (NASDAQ CLBS)
Source:
DateHeadline
Zacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to HoldZacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to Hold
www.americanbankingnews.com - November 16 at 5:34 PM
Caladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment ResearchCaladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
Caladrius Biosciences, Inc. (CLBS) Releases  Earnings Results, Beats Expectations By $0.41 EPSCaladrius Biosciences, Inc. (CLBS) Releases Earnings Results, Beats Expectations By $0.41 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Caladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC WainwrightCaladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 10 at 10:24 AM
Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)
www.globenewswire.com - November 10 at 9:52 AM
What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences, Inc. to Host Earnings CallCaladrius Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences Reports 2017 Third Quarter ResultsCaladrius Biosciences Reports 2017 Third Quarter Results
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences to Participate at Upcoming November Conferences - GlobeNewswire (press release)Caladrius Biosciences to Participate at Upcoming November Conferences - GlobeNewswire (press release)
globenewswire.com - November 2 at 6:08 PM
Caladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern Time
finance.yahoo.com - November 2 at 6:08 PM
Caladrius Biosciences to Participate at Upcoming November ConferencesCaladrius Biosciences to Participate at Upcoming November Conferences
finance.yahoo.com - November 1 at 6:02 PM
Caladrius Biosciences, Inc. (CLBS) Set to Announce Quarterly Earnings on MondayCaladrius Biosciences, Inc. (CLBS) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Caladrius Biosciences, Inc. (CLBS) Downgraded by Zacks Investment ResearchCaladrius Biosciences, Inc. (CLBS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:56 PM
Caladrius Biosciences (CLBS) and Global Blood Therapeutics (GBT) Head-To-Head ReviewCaladrius Biosciences (CLBS) and Global Blood Therapeutics (GBT) Head-To-Head Review
www.americanbankingnews.com - October 11 at 12:08 AM
Head-To-Head Survey: Caladrius Biosciences (CLBS) and Enanta Pharmaceuticals (ENTA)Head-To-Head Survey: Caladrius Biosciences (CLBS) and Enanta Pharmaceuticals (ENTA)
www.americanbankingnews.com - October 6 at 4:28 AM
How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive?How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive?
finance.yahoo.com - October 5 at 11:22 AM
Caladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMDCaladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD
www.streetinsider.com - October 4 at 12:08 PM
Caladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD - StreetInsider.comCaladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD - StreetInsider.com
www.streetinsider.com - October 2 at 10:26 PM
Caladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular DysfunctionCaladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular Dysfunction
finance.yahoo.com - October 2 at 5:25 PM
Caladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the MesaCaladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the Mesa
globenewswire.com - September 28 at 8:42 AM
Why These 4 Biotech Stocks May Not Lose Momentum Soon - NasdaqWhy These 4 Biotech Stocks May Not Lose Momentum Soon - Nasdaq
www.nasdaq.com - September 11 at 5:55 PM
Why These 4 Biotech Stocks May Not Lose Momentum SoonWhy These 4 Biotech Stocks May Not Lose Momentum Soon
finance.yahoo.com - September 11 at 5:55 PM
Type 1 Diabetes May Soon Meet Its MatchType 1 Diabetes May Soon Meet Its Match
finance.yahoo.com - September 8 at 5:40 PM
Caladrius Biosciences to Participate at Upcoming September Conferences - NasdaqCaladrius Biosciences to Participate at Upcoming September Conferences - Nasdaq
www.nasdaq.com - September 8 at 3:21 AM
Caladrius Biosciences to Participate at Upcoming September ConferencesCaladrius Biosciences to Participate at Upcoming September Conferences
finance.yahoo.com - September 7 at 5:19 PM
Caladrius Biosciences (CLBS) "Buy" Rating Reiterated at HC WainwrightCaladrius Biosciences' (CLBS) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 6 at 3:56 PM
Caladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 ... - StreetInsider.comCaladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 ... - StreetInsider.com
www.streetinsider.com - September 5 at 6:47 PM
Caladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 DiabetesCaladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - September 5 at 6:47 PM
Critical Analysis: Arbutus Biopharma Corp (ABUS) and Caladrius Biosciences (CLBS)Critical Analysis: Arbutus Biopharma Corp (ABUS) and Caladrius Biosciences (CLBS)
www.americanbankingnews.com - August 25 at 6:28 AM
Caladrius Biosciences, Inc. (CLBS) PT Set at $7.00 by HC WainwrightCaladrius Biosciences, Inc. (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
Caladrius Biosciences, Inc. (CLBS) Posts  Earnings Results, Beats Estimates By $0.08 EPSCaladrius Biosciences, Inc. (CLBS) Posts Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - August 11 at 12:24 PM
Investor Network: Caladrius Biosciences, Inc. to Host Earnings CallInvestor Network: Caladrius Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - August 10 at 6:29 PM
Caladrius Biosciences Reports 2017 Second Quarter ResultsCaladrius Biosciences Reports 2017 Second Quarter Results
finance.yahoo.com - August 10 at 6:29 PM
Caladrius Biosciences to Host 2017 Second Quarter Results ... - GlobeNewswire (press release)Caladrius Biosciences to Host 2017 Second Quarter Results ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 11:50 PM
Caladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern Time
finance.yahoo.com - August 3 at 6:48 PM
Caladrius Biosciences, Inc. (CLBS) Set to Announce Earnings on MondayCaladrius Biosciences, Inc. (CLBS) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Receives "Buy" Rating from HC WainwrightCaladrius Biosciences, Inc. (NASDAQ:CLBS) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - July 21 at 7:50 AM
Caladrius Biosciences (CLBS) Says 50% of Subjects Have Been ... - StreetInsider.comCaladrius Biosciences (CLBS) Says 50% of Subjects Have Been ... - StreetInsider.com
www.streetinsider.com - July 19 at 11:29 PM
Caladrius Biosciences Announces that 50% of Subjects Have Been Treated in the Phase 2 Clinical Trial of CLBS03 for Type 1 DiabetesCaladrius Biosciences Announces that 50% of Subjects Have Been Treated in the Phase 2 Clinical Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - July 19 at 6:23 PM
ETFs with exposure to Caladrius Biosciences, Inc. : July 12, 2017ETFs with exposure to Caladrius Biosciences, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:53 PM
-$0.96 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter-$0.96 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter
www.americanbankingnews.com - July 4 at 10:28 PM
Caladrius Biosciences Joins Russell Microcap® Index - NasdaqCaladrius Biosciences Joins Russell Microcap® Index - Nasdaq
www.nasdaq.com - June 26 at 5:00 PM
Caladrius Biosciences (CLBS) Presents At 7th Annual LD Micro Invitational Conference - SlideshowCaladrius Biosciences (CLBS) Presents At 7th Annual LD Micro Invitational Conference - Slideshow
seekingalpha.com - June 7 at 7:09 PM
Caladrius Biosciences Announces 2017 First Quarter Financial Results - GlobeNewswire (press release)Caladrius Biosciences Announces 2017 First Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - May 17 at 11:38 AM
Caladrius Biosciences to Participate at Upcoming May Conferences - GlobeNewswire (press release)Caladrius Biosciences to Participate at Upcoming May Conferences - GlobeNewswire (press release)
globenewswire.com - May 1 at 8:39 AM
The Strange Case Of Caladrius Biosciences - Seeking AlphaThe Strange Case Of Caladrius Biosciences - Seeking Alpha
seekingalpha.com - April 19 at 9:21 PM
CALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal OfficersCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 30 at 9:48 PM
CALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD DisclosCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclos
biz.yahoo.com - March 22 at 9:00 PM
Caladrius Biosciences (CLBS) to Sell Remaining Interest to Hitachi Chemical for $75MCaladrius Biosciences (CLBS) to Sell Remaining Interest to Hitachi Chemical for $75M
www.streetinsider.com - March 18 at 4:09 PM
Caladrius Biosciences (CLBS) Climbs as Loss NarrowsCaladrius Biosciences (CLBS) Climbs as Loss Narrows
www.baystreet.ca - March 17 at 3:48 PM

Social Media

Financials

Chart

Caladrius Biosciences (NASDAQ CLBS) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.